Status:
UNKNOWN
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Advanced Esophageal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer.
Eligibility Criteria
Inclusion
- ECOG performance status 0 or 1
- Histologically confirmed advanced esophageal carcinoma
- At least one measurable lesion is present according to the efficacy evaluation criteria for solid tumors (RECIST 1.1)
- Able and willing to provide a written informed consent
Exclusion
- The tumor obviously invades adjacent organs of esophageal lesions
- BMI≤18.5 kg/m2 or weight loss ≥10% within 2 months prior to screening
- Subjects with unresolved adverse effects of prior therapy at the time of enrolment
- Subjects who had received anti-tumor treatments such as surgery, chemotherapy, radiotherapy recently
Key Trial Info
Start Date :
July 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05425472
Start Date
July 27 2022
End Date
March 30 2023
Last Update
September 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032